From concept to the clinic: Retinoic acid receptor α antagonist YCT‐529, an oral non‐hormonal male contraceptive
Andrology · 2026-07 · 14 (5) · 1081-1088
DOI: 10.1111/andr.70106 ↗At a glance
Übersichtsarbeit in Andrology, published online on 2025-08-12. Written by Noha Taher and 2 co-authors. Institution: Department of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, University of Minnesota, Minneapolis, Minnesota, USA. Major MEDLINE topics: Contraceptive Agents, Male, Receptors, Retinoic Acid. Cited 5 times so far (Crossref); 48 references.
Abstract (original language)
YCT‐529 reversibly reduces sperm counts to infertility levels in mice and non‐human primates. Mice mating studies demonstrated 99% effectiveness in preventing pregnancies. YCT‐529 has completed a first‐in‐class, double‐blind, placebo‐controlled Phase I clinical safety study in men and is currently being investigated in a Phase Ib/IIa clinical study.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, University of Minnesota, Minneapolis, Minnesota, USA.
ORCID profiles: Noha Taher, Ehfazul Haque, Gunda I Georg
Cite
APA
Taher, N., Haque, E., & Georg, G. I. (2026). From concept to the clinic: Retinoic acid receptor α antagonist YCT‐529, an oral non‐hormonal male contraceptive. Andrology, 14(5), 1081-1088. https://doi.org/10.1111/andr.70106
Vancouver
Taher N, Haque E, Georg GI. From concept to the clinic: Retinoic acid receptor α antagonist YCT‐529, an oral non‐hormonal male contraceptive. Andrology. 2026;14(5):1081-1088. doi:10.1111/andr.70106
BibTeX
@article{Taher2026,
author = {Taher, Noha and Haque, Ehfazul and Georg, Gunda I},
title = {From concept to the clinic: Retinoic acid receptor α antagonist YCT‐529, an oral non‐hormonal male contraceptive},
journal = {Andrology},
year = {2026},
volume = {14},
number = {5},
pages = {1081--1088},
doi = {10.1111/andr.70106}
}
EUVIMED